TOKYO, May 21, 2019 — Ube Industries, Ltd. today announced that it will construct a fifth pharmaceutical plant on the industrial site of the Ube Chemical Factory in Ube City, Yamaguchi Prefecture.
The fifth pharmaceutical plant will be dedicated to small volume manufacturing of high-potency active pharmaceutical ingredients (APIs). The plant is scheduled to be completed in May 2021 and following a period of trial operations, will start commercial production the following month in June.
In recent years, the pharmaceutical market has shifted from lifestyle disease areas to unmet medical needs such as cancer and rare diseases. As a result, demand is growing for small volume, high-potency APIs. Until now, Ube Industries has developed its pharmaceutical APIs and intermediates business through four manufacturing plants that support medium- and large-scale manufacturing, having started up its first pharmaceutical plant in 1995 and last bringing its fourth plant online in 2011. When built, the fifth pharmaceutical plant will comprehensively engage in development through to commercial production of small volume, high-potency APIs, enabling the business to support a broader range of needs.
The pharmaceuticals business of Ube Industries will seek to realize further growth through internal and joint drug discovery, and API and intermediates manufacturing.
|Building||Steel frame autoclaved lightweight aerated concrete (ALC) construction
Total square footage of 1,000 square meters
|Main Facility Features||Two reactor vessels, filter dryer, pulverizer, kilolab manufacturing system, clean rooms (one each
for reactor vessel and filter dryer, pulverizing, kilolab)